132 related articles for article (PubMed ID: 8653278)
1. Pyridinium cross-links as urinary markers of bone metastases in patients with prostate cancer.
Ikeda I; Miura T; Kondo I
Br J Urol; 1996 Jan; 77(1):102-6. PubMed ID: 8653278
[TBL] [Abstract][Full Text] [Related]
2. Collagen cross-link metabolites in urine as markers of bone metastases in prostatic carcinoma.
Miyamoto KK; McSherry SA; Robins SP; Besterman JM; Mohler JL
J Urol; 1994 Apr; 151(4):909-13. PubMed ID: 7510346
[TBL] [Abstract][Full Text] [Related]
3. Urinary pyridinoline and deoxypyridinoline as potential markers of bone metastasis in patients with prostate cancer.
Takeuchi S; Arai K; Saitoh H; Yoshida K; Miura M
J Urol; 1996 Nov; 156(5):1691-5. PubMed ID: 8863572
[TBL] [Abstract][Full Text] [Related]
4. [Assay of urinary pyridinoline and deoxypyridinoline as potential markers of the rate of bone resorption: usefulness of urinary pyridinoline and deoxypyridinoline in patients with prostate cancer with bone metastases].
Takeuchi S; Yoshida K
Nihon Hinyokika Gakkai Zasshi; 1994 Oct; 85(10):1521-7. PubMed ID: 7990300
[TBL] [Abstract][Full Text] [Related]
5. [The clinical usefulness of urinary pyridinoline and deoxypyridinoline as potential markers of bone metastasis in patients with prostate cancer].
Takeuchi S; Saitoh H
Nihon Rinsho; 1998 Aug; 56(8):2077-81. PubMed ID: 9750511
[TBL] [Abstract][Full Text] [Related]
6. Serum pyridinoline crosslinks as markers of tumour-induced bone resorption.
Nemoto R; Nakamura I; Nishijima Y; Shiobara K; Shimizu M; Takehara T; Ohta T; Kiyoki M
Br J Urol; 1997 Aug; 80(2):274-80. PubMed ID: 9284202
[TBL] [Abstract][Full Text] [Related]
7. Sequential changes of urinary pyridinoline and deoxypyridinoline as markers of metastatic bone tumor in patients with prostate cancer: a preliminary study.
Samma S; Kagebayashi Y; Yasukawa M; Fukui Y; Ozono S; Hirao Y; Sato H; Okajima E
Jpn J Clin Oncol; 1997 Feb; 27(1):26-30. PubMed ID: 9070337
[TBL] [Abstract][Full Text] [Related]
8. Pretreatment levels of urinary deoxypyridinoline as a potential marker in patients with prostate cancer with or without bone metastasis.
Wymenga LF; Groenier K; Schuurman J; Boomsma JH; Elferink RO; Mensink HJ
BJU Int; 2001 Aug; 88(3):231-5. PubMed ID: 11488735
[TBL] [Abstract][Full Text] [Related]
9. Quantitative urinary proteomics using stable isotope labelling by peptide dimethylation in patients with prostate cancer.
Li C; Zang T; Wrobel K; Huang JT; Nabi G
Anal Bioanal Chem; 2015 May; 407(12):3393-404. PubMed ID: 25724369
[TBL] [Abstract][Full Text] [Related]
10. Urinary pyridinoline and deoxypyridinoline in prostate carcinoma patients with bone metastasis.
Sano M; Kushida K; Takahashi M; Ohishi T; Kawana K; Okada M; Inoue T
Br J Cancer; 1994 Oct; 70(4):701-3. PubMed ID: 7917922
[TBL] [Abstract][Full Text] [Related]
11. [Use of urinary hydroxyproline excretion as a marker of bone metastases in prostatic cancer (1)].
Kurokawa K; Imai K; Yamanaka H; Tomaru Y; Kitaura K
Hinyokika Kiyo; 1985 Dec; 31(12):2119-25. PubMed ID: 2421558
[TBL] [Abstract][Full Text] [Related]
12. Bone remodeling markers in the detection of bone metastases in prostate cancer.
de la Piedra C; Castro-Errecaborde NA; Traba ML; Méndez-Dávila C; García-Moreno C; Rodriguez de Acuña L; Rodriguez-Molina J
Clin Chim Acta; 2003 May; 331(1-2):45-53. PubMed ID: 12691863
[TBL] [Abstract][Full Text] [Related]
13. Serum concentration of the pyridinoline crosslinked carboxyterminal telopeptide of type I collagen and urinary concentration of deoxypyridinoline as markers of bone metastases in human prostate carcinoma.
Yoshida K; Hosoya Y; Arai K; Sumi S; Honda M
Clin Chim Acta; 1996 Oct; 254(1):93-5. PubMed ID: 8894314
[No Abstract] [Full Text] [Related]
14. Quantitation of biochemical markers of bone resorption following strontium-89-chloride therapy for metastatic prostatic carcinoma.
Papatheofanis FJ
J Nucl Med; 1997 Aug; 38(8):1175-9. PubMed ID: 9255144
[TBL] [Abstract][Full Text] [Related]
15. Determination of amino acids in urine of patients with prostate cancer and benign prostate growth.
Sroka WD; Boughton BA; Reddy P; Roessner U; Słupski P; Jarzemski P; Dąbrowska A; Markuszewski MJ; Marszałł MP
Eur J Cancer Prev; 2017 Mar; 26(2):131-134. PubMed ID: 27222937
[TBL] [Abstract][Full Text] [Related]
16. Bone-turnover metabolites as clinical markers of bone metastasis in patients with prostatic carcinoma.
Takeuchi S; Saitoh H
Int J Urol; 1997 Jul; 4(4):368-73. PubMed ID: 9256326
[TBL] [Abstract][Full Text] [Related]
17. Pyridinium crosslinks in the monitoring of patients with bone metastases from carcinoma of the breast.
Walne AJ; Jenkins PJ; James IT; Plowman PN
Clin Oncol (R Coll Radiol); 1997; 9(1):30-4. PubMed ID: 9039811
[TBL] [Abstract][Full Text] [Related]
18. Preliminary results of the use of urinary excretion of pyridinium crosslinks for monitoring metastatic bone disease.
Coleman RE; Houston S; James I; Rodger A; Rubens RD; Leonard RC; Ford J
Br J Cancer; 1992 May; 65(5):766-8. PubMed ID: 1586605
[TBL] [Abstract][Full Text] [Related]
19. The diagnostic value of urinary Crosslaps and serum alkaline phosphatase in patients with prostate cancer.
Nguyen-Pamart M; Caty A; Feutrie ML; Fournier C; Gosselin P; Mazeman E
Br J Urol; 1997 Sep; 80(3):452-5. PubMed ID: 9313666
[TBL] [Abstract][Full Text] [Related]
20. [Urinary hydroxyproline excretion as a marker of bone metastasis in prostatic cancer].
Rinsho K
Nihon Hinyokika Gakkai Zasshi; 1983 Jan; 74(1):76-80. PubMed ID: 6191064
[No Abstract] [Full Text] [Related]
[Next] [New Search]
